The CASP6 Knockout CAL-27 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the CAL-27 human oral squamous cell carcinoma line, featuring targeted disruption of the CASP6 gene. This loss-of-function model abolishes caspase-6 expression, enabling researchers to dissect the executioner caspase’s role in apoptosis, inflammation, and neurodegeneration within an epithelial cancer context. The polyclonal knockout format maintains a mixed genetic background, offering a robust system for studying heterogeneous cellular responses without clonal artifacts.
The CAL-27 host cell line was established from a tongue squamous cell carcinoma of a 56-year-old male and serves as a widely used epithelial cancer model for oral squamous cell carcinoma. These adherent cells retain hallmark characteristics of the originating malignancy, including deregulated apoptosis and inflammatory signaling, making them well-suited for investigating caspase-6-dependent pathways in tumor biology. The parental line’s genetic stability and well-documented behavior in standard culture conditions facilitate integration into existing experimental workflows.
Caspase-6 is a cysteine-aspartic protease that functions as an executioner caspase downstream of initiator caspases such as caspase-8 and caspase-9, which are activated by death receptor signaling or granzyme B. Upon activation, caspase-6 interacts with caspase-3 and caspase-7 and is regulated by the inhibitor XIAP. Its canonical substrates include nuclear lamins (lamin A/C) and PARP1, whose cleavage drives nuclear fragmentation and membrane breakdown during apoptosis. The representative pathway comprises Fas ligand, Fas receptor, FADD, caspase-8, caspase-3, caspase-6, and lamin A/C, culminating in irreversible cell death.
In the CAL-27 oral cancer background, CASP6 knockout impairs the execution phase of apoptosis by preventing lamin A/C cleavage and subsequent nuclear demolition, potentially conferring resistance to apoptotic stimuli. This modification allows interrogation of caspase-6’s contributions to both tumor cell survival and inflammatory signaling, given its emerging link to neuroinflammation and innate immunity. The model is particularly valuable for studying oral squamous cell carcinoma’s evasion of cell death and for exploring context-dependent roles of caspase-6 in cancer versus neurodegenerative disease.
Researchers can employ this knockout model for detailed apoptosis-resistance studies using Annexin V/PI staining or TUNEL assays, high-content imaging of nuclear morphology via immunofluorescence, and quantitative western blotting for caspase-6 and cleaved lamin A/C. It is ideal for screening caspase-6 activators, assessing drug sensitivity with viability assays, and investigating neurodegenerative disease mechanisms in an oral cancer setting. Transcript analysis by RT-qPCR and flow cytometric caspase-6 activation measurements complement functional studies. For further information, please contact Ascent Research.
